Which hedge funds own UPB? UPSTREAM BIO INC, Q2 2026 13F holders
36 tracked hedge funds disclosed a position in UPB (UPSTREAM BIO INC) in their Q2 2026 13F filings, worth $128.1m in total. The largest holder by portfolio weight is Decheng Capital LLC at 2.6% of its book. 9 opened a new position this quarter: Verdad Advisers, LP, Voleon Capital Management LP, Walleye Capital LLC, Prelude Capital Management, LLC. 7 exited: Prosight Management, LP, Nantahala Capital Management, LLC, ADAR1 Capital Management, LLC.
- 36
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 9
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 7
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $6.5m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $9.9m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $128m
- Combined value Sum of the holders' reported positions in the security.
- 2.9%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Prosight Management, LP | 0.4% | $2.2m |
| Nantahala Capital Management, LLC | 0.2% | $3.6m |
| ADAR1 Capital Management, LLC | 0.02% | $315k |
| Aquatic Capital Management LLC | 0.01% | $283k |
| Alyeska Investment Group, L.P. | 0.01% | $2.7m |
| Tudor Investment Corp ET AL | 0.0% | $238k |
| Marshall Wace, LLP | 0.0% | $601k |
Ownership over time
Who discovered UPB first? Beta
| Great Point Partners LLC | Q4 2024 | +1.9 pts |
| Venrock Adviser, LLC | Q4 2024 | +1.2 pts |
| Integral Health Asset Management, LLC | Q3 2025 | +0.3 pts |
| Decheng Capital LLC high conviction | Q4 2024 | 0.0 pts |
| Parkman Healthcare Partners LLC | Q3 2025 | −0.1 pts |
| Propel Bio Management, LLC | Q1 2026 | −0.5 pts |
| Lynx1 Capital Management LP | Q4 2024 | −0.5 pts |
| Orbimed Advisors LLC | Q4 2024 | −0.7 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.